CRL

#971
Charles River Laboratories International, Inc.
180.5800 USD
+1.72%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
179.9050
180.6500
Intervallo Annuale
146.4900
228.8800
Variazione giornaliera
+1.72%
Variazione Mensile
+14.69%
Variazione di 6 mesi
-8.27%
Variazione Annuale
-8.27%
Chiusura Precedente
177.5350
Apertura
180.2800
Bid
Ask
Minimo
179.9050
High
180.6500
Volume
85
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 8.8896 B
  • Employee 20 K
  • Founded N/A
  • CEO James C. Foster
  • Website www.criver.com
  • Headquarter Massachusetts, United States
  • FIGI BBG000BG5BL8
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-69.81
Rapporto prezzo/fatturato
2.51

Charles River Laboratories International Inc

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.

Notizie